Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03218163 · ClinicalTrials.gov registry record · Phase 2
MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03218163 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 1 participants.
The verdict
NCT03218163, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Determine the progression free survival of high-risk or relapsed Multiple Myeloma (MM) patients undergoing non-myeloablative bone marrow allogeneic transplantation (NM-AlloSCT) followed by maintenance therapy with MEDI-551.
Interventions
- DRUG MEDI-551 Maintenance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-09-27 |
| Est. Completion | 2018-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03218163
The ClinicalTrials.gov registry entry for NCT03218163 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI-551 Maintenance is the first listed.
NCT03218163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03218163 about?
NCT03218163 is a clinical study titled "MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma". Determine the progression free survival of high-risk or relapsed Multiple Myeloma (MM) patients undergoing non-myeloablative bone marrow allogeneic transplantation (NM-AlloSCT) followed by maintenance therapy with MEDI-551.
What is the current status of trial NCT03218163?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-09-27. Estimated completion is 2018-04-15.
What interventions are being tested in trial NCT03218163?
The interventions under investigation include: MEDI-551 Maintenance (DRUG).
Who is sponsoring clinical trial NCT03218163?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.